United States: Enablement Analysis Requires Showing That Undue Experimentation Would Be Necessary In Order To Practice The Claimed Invention

In Alcon Research Ltd. v. Barr Laboratories, Inc., Nos. 12-1340, -1341 (Fed. Cir. Mar. 18, 2014), the Federal Circuit affirmed the district court's finding of noninfringement by the defendant, Barr Laboratories, Inc. ("Barr"), affirmed the district court's denial of Barr's postjudgment motion to amend for JMOL of noninfringement, and reversed the district court's finding of invalidity for lack of enablement and lack of an adequate written description.   

Alcon Research Ltd. ("Alcon") owns U.S. Patent Nos. 5,631,287 ("the '287 patent") and 6,011,062 ("the '062 patent"), which are directed to methods for enhancing the stability of prostaglandin compositions, including its glaucoma and ocular hypertension drug Travatan Z®, which contains travoprost, the synthetic prostaglandin fluprostenol isopropyl ester.  Claim 1 of the '287 patent reads:  "A method of enhancing the chemical stability of an aqueous composition comprising a therapeutically-effective amount of a prostaglandin, wherein the method comprises adding a chemically-stabilizing amount of a polyethoxylated castor oil [("PECO")] to the composition."  Slip op. at 3 (alteration in original) (citation omitted).  Claim 12, which depends from claim 1, requires that the composition be "a topically administrable ophthalmic composition."  Id. (citation omitted).  Claim 19 of the '062 patent (CIP of the '287 patent) is identical to claim 12 of the '287 patent except that it limits the requisite PECO to one "selected from the group of PEG-5 to PEG-200 hydrogenated castor oils."   Id. (citation omitted).

Barr submitted an ANDA to the FDA, seeking approval of a generic version of Travatan Z®.  Alcon initiated suit, asserting that Barr's ANDA submission infringed claim 12 of the '287 patent and claim 19 of the '062 patent, as well as claims from four other patents, including U.S. Patent Nos. 5,510,383 ("the '383 patent") and 5,889,052 ("the '052 patent").  However, Alcon did not assert the '383 and '052 patents at trial, and neither party adduced any evidence that specifically related to these two patents.  The district court determined that Barr did not infringe the asserted claims, and that the asserted claims were invalid for lack of enablement and written description.  Barr then filed a postjudgment motion pursuant to Fed. R. Civ. P. 59(e) to amend the district court's judgment and to enter JMOL of noninfringement of the '383 and '052 patents.  The motion was denied.  Both parties appealed.   

On appeal, the Federal Circuit first addressed the question of infringement and held that Alcon failed to present evidence of infringement.  Alcon sought to prove that the addition of PECO in Barr's ANDA product would chemically stabilize the prostaglandin travoprost and thus infringe the two asserted claims, and relied on data of a stability study that it conducted during its development work to infer that the addition of PECO would chemically stabilize travoprost in Barr's ANDA composition.  The district court concluded that Barr's ANDA composition was very different from the compositions used in Alcon's study in respect to, e.g., the pH value, concentration of travoprost, concentration of PECO, the presence of antimicrobial preservative, and the buffer solution.  The Federal Circuit affirmed the district court's determination that the Alcon data "had no bearing on whether Barr's proposed generic product infringed Alcon's patents," stating that "[t]he formulations tested in Alcon's stability study were meaningfully different from the product described in Barr's ANDA and thus provided no basis from which to draw any reliable inferences regarding whether the PECO in Barr's composition would chemically stabilize the prostaglandin."  Slip op. at 10.  The Federal Circuit therefore affirmed the district court's holding of noninfringement.

"After the challenger has put forward evidence that some experimentation is needed to practice the patented claim, the factors set forth in Wands then provide the factual considerations that a court may consider when determining whether the amount of that experimentation is either 'undue' or sufficiently routine such that an ordinarily skilled artisan would reasonably be expected to carry it out."  Slip op. at 12 (citing In re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988)).

The Federal Circuit next addressed the question of enablement, agreeing with Alcon that the district court erred in its enablement analysis.  The Court held that Barr had the burden of proof to show that Alcon's patents lacked enabling disclosures, but failed to carry that burden.  Noting that the factors set forth in In re Wands, 858 F.2d 731 (Fed. Cir. 1988), require a challenger to show by clear and convincing evidence that a person of ordinary skill in the art would not be able to practice the claimed invention without undue experimentation, the Court found that Barr "proffered no evidence that any experimentation, let alone undue experimentation, . . . would be necessary in order to practice the claimed invention.  Without that evidence, there is no foundation for the district court's nonenablement ruling."  Slip op. at 13. 

Turning to the written description requirement, the Federal Circuit explained that there is no requirement that the disclosure contain either examples or an actual reduction to practice; rather, the critical inquiry is whether the patentee has provided a description that in a definite way identifies the claimed invention in sufficient detail that a person of ordinary skill would understand that the inventor was in possession of it at the time of filing.  The Court noted that the '287 patent details the claimed invention and discloses a step-by-step description of how a person of ordinary skill in the art may use the invention, provides exemplary formulations and discloses data from accelerated stability testing showing the effect of PECO and prostaglandin concentration on stability, and describes various classes of prostaglandins and various types of PECOs and other formulation parameters.  The '062 patent, a CIP of the '287 patent, includes additional disclosures regarding preferred PECOs and prostaglandins, and three additional examples. The Court noted that Barr adduced no evidence, let alone clear and convincing evidence, of a lack of written description to an ordinarily skilled artisan.  Thus, the Court held that the disclosures of the '287 and '062 patents demonstrated that the inventors conceived of and described their invention at the time the applications were filed, and "[t]hat is all that the written description requirement demands."  Id. at 17. 

Finally, the Court addressed Barr's Rule 59(e) postjudgment motion to amend judgment and to enter JMOL of noninfringement of the '383 and '052 patents.  The Court adopted the law of the Third Circuit because the issues were of a procedural nature.  Alcon informed Barr of its decision to drop the '383 and '052 patents, and Barr subsequently omitted them from the pretrial order.  Thus, the Court noted that the '383 and '052 patents were not litigated, or fairly placed in issue, during the trial.  The Court found that "a patentee's announcement that it was no longer pursuing particular claims, coupled with its ceasing to litigate them, was sufficient to remove those claims from the case even without such formalities."  Id. at 20.  In addition, the Court noted that Barr did not file a counterclaim for DJ of noninfringement of the patents, and as a result, "it is up to the patentee to decide what claims are to be litigated and decided at trial."  Id. at 21.  Accordingly, the Court affirmed the district court's decision to deny Barr's Rule 59(e) motion.

Judges: Newman, Lourie (author), Bryson

[Appealed from D. Del., Judge Davis]

This article previously appeared in Last Month at the Federal Circuit, April 2014.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
27 Jan 2019, Other, Washington, DC, United States

Finnegan is a sponsor of the Association of Corporate Patent Counsel Winter Meeting. Finnegan partner Erika Arner will join the panel discussion “PTAB Review & Litigation.”

27 Jan 2019, Other, Florida, United States

Finnegan is a sponsor of the Association of Corporate Patent Counsel Winter Meeting. Finnegan partner Erika Arner will join the panel discussion “PTAB Review & Litigation.

28 Jan 2019, Other, Washington, DC, United States

Finnegan is a Gold sponsor of IAM Magazine’s second annual Pharma & Biotech IP Summit. Finnegan partner Anthony Tridico will moderate the panel discussion “Overcoming the Barriers to Building a Successful IP Business Strategy.”

Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions